DALLAS, March 11, 2015 /PRNewswire/ --
RnRMarketResearch.com adds "Dilated Cardiomyopathy - Pipeline Review, H1 2015" therapeutic market research report of 56 pages with latest updates, data and information to its online business intelligence library.
The report Dilated Cardiomyopathy Pipeline Review, H1 2015 provides an overview of the Dilated Cardiomyopathy's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Dilated Cardiomyopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dilated Cardiomyopathy and special features on late-stage and discontinued projects.
Dilated cardiomyopathy is a condition in which the heart becomes weakened and enlarged. This condition is the most common form of cardiomyopathy and accounts for approximately 55-60% of all childhood cardiomyopathies. It can have both genetic and infectious/environmental causes. It is more commonly diagnosed in younger children with the average age at diagnosis being 2 years. Dilated cardiomyopathy can appear along a spectrum of no symptoms, subtle symptoms or, in the more severe cases, congestive heart failure (CHF), which occurs when the heart is unable to pump blood well enough to meet the body tissue needs for oxygen and nutrients.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Companies discussed in this report include: Array BioPharma Inc., Kasiak Research Pvt. Ltd., Sanofi, Vericel Corporation, Zensun (Shanghai) Sci & Tech Co., Ltd. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=310165 . (This is a premium report priced at US$2000 for a single user License.)
Drugs profile discussed in this report include: ARRY-797, CAP-1002, ixmyelocel-T, Neucardin, Refacell-DCM, Small Molecule for Dilated Cardiomyopathy and Small Molecule for Dilated Cardiomyopathy.
Featured News & Press Releases cover by this report include: Dec 19, 2013: Aastrom Biosciences Granted Composition-of-Matter Patent for Ixmyelocel-T in Australia; Dec 17, 2013: Capricor Therapeutics Cleared to Begin Phase II Portion of ALLSTAR Clinical Trial with CAP-1002 in Patients Following Heart Attack; Apr 19, 2013: Aastrom Biosciences Announces First Patients Treated In IxCELL-DCM Clinical Study Of Ixmyelocel-T; Jun 06, 2012: Aastrom Presents Preclinical Data Of Ixmyelocel-T At 18th Annual International Society For Cellular Therapy Meeting; May 10, 2012: Treatment With Ixmyelocel-T Shows Improvement In Outcome Of Heart Failure Patients; May 07, 2012: Aastrom To Present Phase IIa Trial Results Of Ixmyelocel-T In Dilated Cardiomyopathy Patients At SCAI Scientific Sessions; Oct 03, 2011: Aastrom Receives European Composition-Of-Matter Patent For Ixmyelocel-T; Sep 19, 2011: Aastrom Announces Positive 12-Month Safety And Efficacy Data From IMPACT-DCM Phase II Clinical Trial For Ixmyelocel-T In Treatment Of Dilated Cardiomyopathy; Sep 14, 2011: Aastrom To Present 12-Month Data From IMPACT-DCM Phase II Clinical Trial For Ixmyelocel-T In Treatment Of Dilated Cardiomyopathy; May 17, 2011: Aastrom To Present Results From Two Studies of Ixmyelocel-T At International Society For Cellular Therapy Meeting.
Global Markets Direct reports feature investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by an expert team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information.
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Dilated Cardiomyopathy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Dilated Cardiomyopathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Explore more reports of cardiovascular therapeutics Market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/cardiovascular-therapeutics .
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
Connect with Us:
G+ / Google Plus: https://plus.google.com/u/0/104156468549256253075/
RSS / Feeds: http://www.rnrmarketresearch.com/feed
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
SOURCE RnR Market Research